Impact of a Gene Test for Susceptibility to Lung Cancer in Smokers
Smoking Cessation
About this trial
This is an interventional prevention trial for Smoking Cessation focused on measuring Nicotine addiction, Behaviour, Gene test, Lung cancer, Lifetime risk of lung cancer in smokers
Eligibility Criteria
Inclusion Criteria:
- Aged 20-70 years
- Smoking more than 10 cigarettes daily
Exclusion Criteria:
- Aged under 20 years or over 70 years
- Smoking less than 10 cigarettes daily
- History of major depression and other psychiatric conditions, dementias and serious or terminal illness (cancers etc.).
- Patients on warfarin would be excluded due to interactions between warfarin and varenicline as varenicline will be used as the modern treatment of choice for smoking cessation.
Patients who did not wish to have a genetic test would be referred to the practice nurse for smoking cessation.
Sites / Locations
- The Integrated Care Partnership The Old Cottage Hospital Alexandra Road,
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control group
Respiragene test and risk score
The control group will have a standard NHS cessation clinic experience
Subjects will have a buccal swab taken at first attendance for a 12 gene test of SNP variants associated with risk of lung cancer. From the genetic data and clinical data (any history of COPD, family history of lung cancer in a first degree relative and age) a risk score is calculated from which a lifetime risk of lung cancer if the subject continues to smoke can be calculated. This is expected to be a powerful motivator to encourage smoking cessation.